157 related articles for article (PubMed ID: 38521388)
1. Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology.
Zahra N; Rafique S; Naveed Z; Nadeem J; Waqas M; Ali A; Shah M; Idrees M
Life Sci; 2024 May; 345():122565. PubMed ID: 38521388
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
Wu C; Rajagopalan S
Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of phosphodiesterase 4 in activated hepatic stellate cells promotes cytoskeleton remodeling and cell migration.
Elnagdy M; Wang Y; Rodriguez W; Zhang J; Bauer P; Wilkey DW; Merchant M; Pan J; Farooqui Z; Cannon R; Rai S; Maldonado C; Barve S; McClain CJ; Gobejishvili L
J Pathol; 2023 Nov; 261(3):361-371. PubMed ID: 37735782
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.
Avila DV; Barker DF; Zhang J; McClain CJ; Barve S; Gobejishvili L
J Pathol; 2016 Sep; 240(1):96-107. PubMed ID: 27287961
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench.
Rodriguez WE; Wahlang B; Wang Y; Zhang J; Vadhanam MV; Joshi-Barve S; Bauer P; Cannon R; Ahmadi AR; Sun Z; Cameron A; Barve S; Maldonado C; McClain C; Gobejishvili L
Hepatology; 2019 Dec; 70(6):1958-1971. PubMed ID: 31081957
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
Tao X; He H; Peng J; Xu R; Fu J; Hu Y; Li L; Yang X; Feng X; Zhang C; Zhang L; Yu X; Shen A; Huang K; Fu Q
Pharmacol Res; 2022 Jan; 175():106004. PubMed ID: 34826603
[TBL] [Abstract][Full Text] [Related]
7. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
8. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
Kimura T; Singh S; Tanaka N; Umemura T
Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway.
Zhang T; Hu J; Wang X; Zhao X; Li Z; Niu J; Steer CJ; Zheng G; Song G
J Hepatol; 2019 Jan; 70(1):87-96. PubMed ID: 30218679
[TBL] [Abstract][Full Text] [Related]
10. Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4.
Gobejishvili L; Barve S; Breitkopf-Heinlein K; Li Y; Zhang J; Avila DV; Dooley S; McClain CJ
J Pharmacol Exp Ther; 2013 Oct; 347(1):80-90. PubMed ID: 23887098
[TBL] [Abstract][Full Text] [Related]
11. Decoding cell death signals in liver inflammation.
Brenner C; Galluzzi L; Kepp O; Kroemer G
J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
13. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
14. Role of cAMP and phosphodiesterase signaling in liver health and disease.
Wahlang B; McClain C; Barve S; Gobejishvili L
Cell Signal; 2018 Sep; 49():105-115. PubMed ID: 29902522
[TBL] [Abstract][Full Text] [Related]
15. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.
Katsarou A; Moustakas II; Pyrina I; Lembessis P; Koutsilieris M; Chatzigeorgiou A
World J Gastroenterol; 2020 May; 26(17):1993-2011. PubMed ID: 32536770
[TBL] [Abstract][Full Text] [Related]
16. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
[TBL] [Abstract][Full Text] [Related]
17. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.
Ipsen DH; Skat-Rørdam J; Tsamouri MM; Latta M; Lykkesfeldt J; Tveden-Nyborg P
Mol Genet Genomics; 2019 Jun; 294(3):649-661. PubMed ID: 30759275
[TBL] [Abstract][Full Text] [Related]
18. Activation of SIK1 by phanginin A inhibits hepatic gluconeogenesis by increasing PDE4 activity and suppressing the cAMP signaling pathway.
Liu S; Huang S; Wu X; Feng Y; Shen Y; Zhao QS; Leng Y
Mol Metab; 2020 Nov; 41():101045. PubMed ID: 32599076
[TBL] [Abstract][Full Text] [Related]
19. Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches.
Tibbo AJ; Tejeda GS; Baillie GS
Biochem Soc Trans; 2019 Oct; 47(5):1557-1565. PubMed ID: 31642904
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
Jin SL; Ding SL; Lin SC
Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
